Figure 4.

Metastatic castration‐resistant prostate cancer (mCRPC) drug usage proportion among docetaxel‐naïve and post‐docetaxel patients by age group in the 2010–2013 commercial claims cohort. In each of the age groups (44–64, 65–80, >80 years), the drug usage proportion of abiraterone acetate (P < 0.0001) and enzalutamide (P = 0.0003) was significantly different between the docetaxel‐naïve and post‐docetaxel settings, whereas the drug usage proportion of sipuleucel‐T (P = 0.40) and cabazitaxel (P = 0.42) was not significantly different between the docetaxel‐naïve and post‐docetaxel settings.